A Key Mitotic Checkpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW YORK and HONG KONG, June 14, 2022 /PRNewswire/ Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the initiation of patient dosing in TWT-203, its Phase 1b/2 study to evaluate CFI-402257, an oral, best-in-class inhibitor of Threonine Tyrosine Kinase (TTK, also known as MPS1) in patients with advanced solid tumors and ER+/Her2- breast cancer. Dosing of the first patient in the trial commenced June 8that START Mountain Region in Salt Lake City, Utah. "Inhibition of TTK, a key mitotic checkpoint, with CFI-402257 represents a novel treatment approach for ER+/Her2-breast cancer, particularly in the context of CDK4/6 inhibitor failure" said Principal Investigator, Dr. Justin A. Call, MD, Director of Clinical Researchat START Mountain Region in Salt Lake City, Utah. "We are excited about the initiation of TWT-203 with our potent and selective TTK inhibitor," said Dr. Michael Tusche, Tre ....

United States , Salt Lake , Clinical Research , Salt Lake City , Principal Investigator , Michael Tusche , Recommended Phase , New York And Hong Kong , June 14 , 022 Prnewswire Treadwell Therapeutics , A Clinical Stage Biotechnology Company Developing Novel Medicines For Unmet Needs In Cancer , Oday Announced The Initiation Of Patient Dosing In Twt 203 , Ts Phase 1b 2 Study To Evaluate Cfi 402257 , N Oral , Est In Class Inhibitor Of Threonine Tyrosine Kinase Ttk , Lso Known As Mps1 In Patients With Advanced Solid Tumors And Er Her2 Breast Cancer Dosing Of The First Patient Trial Commenced June 8that Start Mountain Region Salt Lake City , Tah Quot Inhibition Of Ttk , A Key Mitotic Checkpoint , Ith Cfi 402257 Representsa Novel Treatment Approach For Er Her2 Breast Cancer , Articularly In The Context Of Cdk4 6 Inhibitor Failure Quot Said Principal Investigator , R Justina Call , Irector Of Clinical Researchat Start Mountain Region In Salt Lake City , Tah Quot We Are Excited About The Initiation Of Twt 203 With Our Potent And Selective Ttk Inhibitor , Uot Said Dr Michael Tusche , Readwell Co Ceo Quot Previous Clinical Studies Have Demonstrated That Cfi 402257 Hasa Tolerable Safety Profile And Confirmed Responses In Er Her2 Breast Cancer After Progression On Cdk4 6 Inhibitors We Look Forward To The Continued Development Of This Molecule Phase 1b 2 Trial Is An Open Label , Multi Center ,